SlideShare a Scribd company logo
2011 Organ Donation Congress Buenos Aires Alejandra Villamil Hospital Italiano de Buenos Aires “ Donor  Risk Index in Liver Transplantation”
Liver Transplantation “ A dance for two”
Liver Transplantation Ideal Donor Ideal Recipient Ideal “couple” Optimal patient and graft survival
Ideal Donor Ideal Recipient Ideal “couple” Do we always get what we want? Optimal patient and graft survival
The Transplant Scenario Critical scarcity of cadaveric donors  ,[object Object],[object Object],[object Object]
Strategies to overcome organ scarcity Expand the donor pool Optimize the distribution of available organs ,[object Object],[object Object],[object Object],[object Object],[object Object]
Strategies to overcome organ scarcity Expand the donor pool Optimize the distribution of available organs ,[object Object],[object Object],The strongest answer  to the organ shortage problem
Extended Criteria Donors Donor with risk factors for early or delayed graft dysfunction Disease transmission ,[object Object],[object Object],Functional Risk
Extended Criteria Donors Donor with risk factors for early or delayed graft dysfunction Disease transmission ,[object Object],[object Object],Functional Risk Dychotomic variable (yes / no) Continous variable Every donor has an individual functional risk
Assesment of Organs Functional Risk Donor Risk Index Quantitative scale based on  8 donor variables that defines a relative risk of graft failure Feng S. AJT 2006 Apr; 6(4):783790 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Provides Objectivity Reproducibility Comparability *All variables knowable at the time of offering ,[object Object],[object Object],[object Object]
The increase in the number of livers parallels an increase in the average DRI, corresponding to a decrease in organ quality Graft Quality in Adult Liver Transplants The historical perspective Median Donor Risk Index in successive years SRTR 2005
What is the cost of lower quality organs? Lower quality organs “do worst” than ideal organs Feng S. AJT 2006 Apr; 6(4):783790 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],The “more s ” of ECD Adjusted graft survival by Donor Risk Index
What is the cost of lower quality organs? Lower quality organs “do worst” than ideal organs Feng S. AJT 2006  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],The “mores” of ECD Adjusted graft survival by Donor Risk Index Who will carry the burden?
Impact of donor quality on transplant outcomes “ Best organs for the sickest patients” Unable to survive the additional challenge of a poor quality organ SRTR Median Donor Risk Index (DRI)by MELD at Transplant Liver utilization practices
Is it fair to expose the healthiest candidates, who benefit the least from transplantation, to bear the additional burden of high risk grafts? Impact of donor quality on transplant outcomes “ Worst organs for the healthiest patients”
What is the impact of ECD across MELD Scores? Analysis of the outcome of transplantation with EDC (DRI >1.7) stratified by MELD Score The higher risk of graft failure for low quality organs remained stable across MELD categories The impact of suboptimal graft quality is not magnified by increased recipient severity Maluf, D.G. Transplantation 2006
Combined impact of graft quality and disease severity Schaubel D, ATC 2006 Survival benefit  for MELD >18 with high DRI organs Survival benefit  for MELD >15 -17 with medium DRI organs Survival benefit  for MELD >12 -14 with low DRI organs MELD <12 negative survival benefit from transplantation Intention to Treat analysis:  What is the risk of doing the transplant with this graft versus the risk of not doing the transplant for a given recipient. Elective Risk of Death in first year  Transplantation of the sickest candidates with lower quality livers may be justifiable and appropriate
Combined impact of graft quality and disease severity Schaubel D, ATC 2006 Survival benefit  for MELD >18 with high DRI organs Survival benefit  for MELD >15 -17 with medium DRI organs Survival benefit  for MELD >12 -14 with low DRI organs MELD <12 negative survival benefit from transplantation Intention to Treat analysis:  What is the risk of doing the transplant with this graft versus the risk of not doing the transplant for a given recipient. Elective Risk of Death in first year  Low MELD candidates transplantation with poor quality organs might be deleterious !
Economic impact of ECDs on Transplantation High MELD score is the strongest predictor of liver transplant costs. Washburn W.K  , Am J Transplant  2006. Axelrod, D.A. Am J Transplant  2007 DRI has been reported to increase hospital costs independently of the recipient status Average hospital charges by donor quality Sickest candidates High MELD score  Poor quality organ High DRI + Higher costs Can we pay the price?
Lucas McCormack, HPB World Congress 2010 Other alternatives for  “ livers that nobody wants” Analysis of the experience in Hospital Aleman de Buenos Aires Are the two groups comparable?  ECD could be an alternative for patients “underserved” by MELD Score distribution (ie HCC over Milan criteria, refractory ascites, HIV + patients) LNW (n=26) Control (n=25) p value Time in our LT Program (days) 53 (1-696) 42 (1-788) 0.72 Position on the WL 71 (31-432) 18 (2-29) <0.001 MELD score 13 (6-21) 18 (6-34) 0.02 MELD corrected 13 (6-21) 22 (7-34) <0.001 Donor risk factors  (≤2 vs.   3-4 factors) 11/ 15 19/6 0.03
Should donor and recipient be matched in liver transplantation?
Ethics of ECD Which principles should guide allocation of ECDs?  Maximize utility Maximize survival benefit Higher post Tx survival Considering in-list mortality and post Tx survival ECDs for low MELD scores ECDs for high MELD scores ALERT !  Deterioration of transplant outcomes among candidates with MELD < 20 has been attributed to the use of high DRI organs  Volk,  ECDs for other patients
Which principles should guide allocation of ECDs?  Decision making Recipient disease severity (MELD score) Donor quality (Donor Risk Index) Logistics Estimated ischemia time Opprtunity for another offer Consider time! Each decission should be taken in a case by case basis
Disciplina de Transplante de Fígado - FMUSP n = 204 Prof. Dr. Luiz Augusto Carneiro D’Albuquerque ECDs: What proportion of the donor pool? The proportion of ECDs is expected to keep growing The Brazil example
Meses % sobrevida USA SSESP American Transplant Registry  ( Estado de São Paulo) Significant increase in ECDs is expected to impact transplant results Are doctors and patients ready to pay the prize? Prof. Dr. Luiz Augusto Carneiro D’Albuquerque The Brazil example ECDs: What proportion of the donor pool?
In conclusion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The introduction of ECDs is today a most important strategy to fight  organ shortage

More Related Content

What's hot

Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
spa718
 
Graft versus Tumour effect
Graft versus Tumour effectGraft versus Tumour effect
Graft versus Tumour effect
meducationdotnet
 
Аллопуринол и прогрессирование ХБП и кардиоваскулярные события. РКИ / Allopur...
Аллопуринол и прогрессирование ХБП и кардиоваскулярные события. РКИ / Allopur...Аллопуринол и прогрессирование ХБП и кардиоваскулярные события. РКИ / Allopur...
Аллопуринол и прогрессирование ХБП и кардиоваскулярные события. РКИ / Allopur...
hivlifeinfo
 
Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignanci...
Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignanci...Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignanci...
Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignanci...
cordbloodsymposium
 
Advancing Dialysis - Quality of Life
Advancing Dialysis - Quality of LifeAdvancing Dialysis - Quality of Life
Advancing Dialysis - Quality of Life
AdvancingDialysis.org
 
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...Contemporary Management of HIV.How Common Comorbidities Affect ART Management...
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...
hivlifeinfo
 
Vitamin D Pleiotropy after Renal Transplantation_Crimson Publishers
Vitamin D Pleiotropy after Renal Transplantation_Crimson PublishersVitamin D Pleiotropy after Renal Transplantation_Crimson Publishers
Vitamin D Pleiotropy after Renal Transplantation_Crimson Publishers
CrimsonPublishersUrologyJournal
 
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
hivlifeinfo
 
International Biobanking: Oportunities and Challenges for Private-Public Coll...
International Biobanking: Oportunities and Challenges for Private-Public Coll...International Biobanking: Oportunities and Challenges for Private-Public Coll...
International Biobanking: Oportunities and Challenges for Private-Public Coll...
BBMRI Stakeholder's Forum
 
Kidney Donor Profile Index (KDPI)
Kidney Donor Profile Index (KDPI)Kidney Donor Profile Index (KDPI)
Kidney Donor Profile Index (KDPI)
Goutham Kumar
 
Blood Conservation Initiative - Craig Rhyne, Covenant Health
Blood Conservation Initiative - Craig Rhyne, Covenant HealthBlood Conservation Initiative - Craig Rhyne, Covenant Health
Blood Conservation Initiative - Craig Rhyne, Covenant Health
Healthcare Network marcus evans
 
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...
hivlifeinfo
 
Who should undergo genetic testing
Who should undergo genetic testingWho should undergo genetic testing
Who should undergo genetic testing
drucsamal
 
Web cast cancer gene panels march 11 2015
Web cast cancer gene panels march 11 2015Web cast cancer gene panels march 11 2015
Web cast cancer gene panels march 11 2015
Andreas Scherer
 
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...
hivlifeinfo
 
Contemporary Management of HIV.How Aging Affects ART Management.2018
Contemporary Management of HIV.How Aging Affects ART Management.2018Contemporary Management of HIV.How Aging Affects ART Management.2018
Contemporary Management of HIV.How Aging Affects ART Management.2018
hivlifeinfo
 
BONUS: John Rudrud Be the Match Strategy Overview Slides
BONUS: John Rudrud Be the Match Strategy Overview SlidesBONUS: John Rudrud Be the Match Strategy Overview Slides
BONUS: John Rudrud Be the Match Strategy Overview Slides
Balanced Scorecard Institute-Spider Strategies Strategy Execution Summit 2015
 
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...
hivlifeinfo
 
Antiretroviral Therapy Update 2016
Antiretroviral Therapy Update 2016Antiretroviral Therapy Update 2016
Antiretroviral Therapy Update 2016
hivlifeinfo
 
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...
hivlifeinfo
 

What's hot (20)

Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
 
Graft versus Tumour effect
Graft versus Tumour effectGraft versus Tumour effect
Graft versus Tumour effect
 
Аллопуринол и прогрессирование ХБП и кардиоваскулярные события. РКИ / Allopur...
Аллопуринол и прогрессирование ХБП и кардиоваскулярные события. РКИ / Allopur...Аллопуринол и прогрессирование ХБП и кардиоваскулярные события. РКИ / Allopur...
Аллопуринол и прогрессирование ХБП и кардиоваскулярные события. РКИ / Allopur...
 
Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignanci...
Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignanci...Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignanci...
Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignanci...
 
Advancing Dialysis - Quality of Life
Advancing Dialysis - Quality of LifeAdvancing Dialysis - Quality of Life
Advancing Dialysis - Quality of Life
 
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...Contemporary Management of HIV.How Common Comorbidities Affect ART Management...
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...
 
Vitamin D Pleiotropy after Renal Transplantation_Crimson Publishers
Vitamin D Pleiotropy after Renal Transplantation_Crimson PublishersVitamin D Pleiotropy after Renal Transplantation_Crimson Publishers
Vitamin D Pleiotropy after Renal Transplantation_Crimson Publishers
 
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
 
International Biobanking: Oportunities and Challenges for Private-Public Coll...
International Biobanking: Oportunities and Challenges for Private-Public Coll...International Biobanking: Oportunities and Challenges for Private-Public Coll...
International Biobanking: Oportunities and Challenges for Private-Public Coll...
 
Kidney Donor Profile Index (KDPI)
Kidney Donor Profile Index (KDPI)Kidney Donor Profile Index (KDPI)
Kidney Donor Profile Index (KDPI)
 
Blood Conservation Initiative - Craig Rhyne, Covenant Health
Blood Conservation Initiative - Craig Rhyne, Covenant HealthBlood Conservation Initiative - Craig Rhyne, Covenant Health
Blood Conservation Initiative - Craig Rhyne, Covenant Health
 
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...
 
Who should undergo genetic testing
Who should undergo genetic testingWho should undergo genetic testing
Who should undergo genetic testing
 
Web cast cancer gene panels march 11 2015
Web cast cancer gene panels march 11 2015Web cast cancer gene panels march 11 2015
Web cast cancer gene panels march 11 2015
 
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...
 
Contemporary Management of HIV.How Aging Affects ART Management.2018
Contemporary Management of HIV.How Aging Affects ART Management.2018Contemporary Management of HIV.How Aging Affects ART Management.2018
Contemporary Management of HIV.How Aging Affects ART Management.2018
 
BONUS: John Rudrud Be the Match Strategy Overview Slides
BONUS: John Rudrud Be the Match Strategy Overview SlidesBONUS: John Rudrud Be the Match Strategy Overview Slides
BONUS: John Rudrud Be the Match Strategy Overview Slides
 
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...
 
Antiretroviral Therapy Update 2016
Antiretroviral Therapy Update 2016Antiretroviral Therapy Update 2016
Antiretroviral Therapy Update 2016
 
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...
 

Similar to Alejandra Villamil - Argentina - Tuesday 29 - Organ Allocation Optimizing donor-recipient match

Aeha cea- shaw
Aeha   cea- shawAeha   cea- shaw
Jesse Schold - USA - Tuesday 29 - Organ Allocation Optimizing donor-recipien...
Jesse Schold  - USA - Tuesday 29 - Organ Allocation Optimizing donor-recipien...Jesse Schold  - USA - Tuesday 29 - Organ Allocation Optimizing donor-recipien...
Jesse Schold - USA - Tuesday 29 - Organ Allocation Optimizing donor-recipien...
incucai_isodp
 
Pathophysiology Of Heart Failure
Pathophysiology Of Heart FailurePathophysiology Of Heart Failure
Pathophysiology Of Heart Failure
Stephanie King
 
Red cell alloimmunization in blood transfusion dependent Patients with Sickle...
Red cell alloimmunization in blood transfusion dependent Patients with Sickle...Red cell alloimmunization in blood transfusion dependent Patients with Sickle...
Red cell alloimmunization in blood transfusion dependent Patients with Sickle...
iosrjce
 
Final FRD
Final FRDFinal FRD
Final FRD
Nina Shedd
 
Prof. Seamas Donnelly
Prof. Seamas DonnellyProf. Seamas Donnelly
Prof. Seamas Donnelly
CASALA CENTRE
 
Shape aha 2005
Shape   aha 2005Shape   aha 2005
Chronic venous diseases how to improve your patient quality of life
Chronic venous diseases how to improve your patient quality of lifeChronic venous diseases how to improve your patient quality of life
Chronic venous diseases how to improve your patient quality of life
Suharti Wairagya
 
Adult to adult living donor liver transplantation
Adult to adult living donor liver transplantationAdult to adult living donor liver transplantation
Adult to adult living donor liver transplantation
Mohammad Goouda
 
Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...
Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...
Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...
Anya Ragnhildstveit
 
La mia esperienza innovativa è... la perfusione degli organi
La mia esperienza innovativa è... la perfusione degli organiLa mia esperienza innovativa è... la perfusione degli organi
La mia esperienza innovativa è... la perfusione degli organi
Network Trapianti
 
Comorbidities and Other Predictors for Severity of Colonic Diverticulitis?
Comorbidities and Other Predictors for Severity of Colonic Diverticulitis?Comorbidities and Other Predictors for Severity of Colonic Diverticulitis?
Comorbidities and Other Predictors for Severity of Colonic Diverticulitis?
semualkaira
 
PBM. MANEJO DE LA ANEMIA PREOPERATORIA. Dr García Erce. Roma 2015
PBM. MANEJO DE LA ANEMIA PREOPERATORIA. Dr García Erce. Roma 2015PBM. MANEJO DE LA ANEMIA PREOPERATORIA. Dr García Erce. Roma 2015
PBM. MANEJO DE LA ANEMIA PREOPERATORIA. Dr García Erce. Roma 2015
José Antonio García Erce
 
PBM. Preoperative Anemia Management, Dr García Erce. Roma 2015
PBM. Preoperative Anemia Management, Dr García Erce. Roma 2015PBM. Preoperative Anemia Management, Dr García Erce. Roma 2015
PBM. Preoperative Anemia Management, Dr García Erce. Roma 2015
José Antonio García Erce
 
Francesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor RiskFrancesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor Risk
incucai_isodp
 
Donor Selection: Sibling. Prof Miguel A Sanz
Donor Selection: Sibling. Prof Miguel A SanzDonor Selection: Sibling. Prof Miguel A Sanz
Donor Selection: Sibling. Prof Miguel A Sanz
spa718
 
Esrd in elderly patients 2019 latest
Esrd in elderly patients 2019 latestEsrd in elderly patients 2019 latest
Esrd in elderly patients 2019 latest
FAARRAG
 
marcqi_blood_transfusion.pdfUNDERSTAND WORD FEATURE
marcqi_blood_transfusion.pdfUNDERSTAND WORD FEATUREmarcqi_blood_transfusion.pdfUNDERSTAND WORD FEATURE
marcqi_blood_transfusion.pdfUNDERSTAND WORD FEATURE
SKGAMING32
 
Hemodialysis.com | Kidney Disease | ESRD | Dialysis
Hemodialysis.com | Kidney Disease | ESRD | DialysisHemodialysis.com | Kidney Disease | ESRD | Dialysis
Hemodialysis.com | Kidney Disease | ESRD | Dialysis
Marie Benz MD FAAD
 
Solid Organ Transplantation and HIV
Solid Organ Transplantation and HIVSolid Organ Transplantation and HIV
Solid Organ Transplantation and HIV
UC San Diego AntiViral Research Center
 

Similar to Alejandra Villamil - Argentina - Tuesday 29 - Organ Allocation Optimizing donor-recipient match (20)

Aeha cea- shaw
Aeha   cea- shawAeha   cea- shaw
Aeha cea- shaw
 
Jesse Schold - USA - Tuesday 29 - Organ Allocation Optimizing donor-recipien...
Jesse Schold  - USA - Tuesday 29 - Organ Allocation Optimizing donor-recipien...Jesse Schold  - USA - Tuesday 29 - Organ Allocation Optimizing donor-recipien...
Jesse Schold - USA - Tuesday 29 - Organ Allocation Optimizing donor-recipien...
 
Pathophysiology Of Heart Failure
Pathophysiology Of Heart FailurePathophysiology Of Heart Failure
Pathophysiology Of Heart Failure
 
Red cell alloimmunization in blood transfusion dependent Patients with Sickle...
Red cell alloimmunization in blood transfusion dependent Patients with Sickle...Red cell alloimmunization in blood transfusion dependent Patients with Sickle...
Red cell alloimmunization in blood transfusion dependent Patients with Sickle...
 
Final FRD
Final FRDFinal FRD
Final FRD
 
Prof. Seamas Donnelly
Prof. Seamas DonnellyProf. Seamas Donnelly
Prof. Seamas Donnelly
 
Shape aha 2005
Shape   aha 2005Shape   aha 2005
Shape aha 2005
 
Chronic venous diseases how to improve your patient quality of life
Chronic venous diseases how to improve your patient quality of lifeChronic venous diseases how to improve your patient quality of life
Chronic venous diseases how to improve your patient quality of life
 
Adult to adult living donor liver transplantation
Adult to adult living donor liver transplantationAdult to adult living donor liver transplantation
Adult to adult living donor liver transplantation
 
Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...
Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...
Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...
 
La mia esperienza innovativa è... la perfusione degli organi
La mia esperienza innovativa è... la perfusione degli organiLa mia esperienza innovativa è... la perfusione degli organi
La mia esperienza innovativa è... la perfusione degli organi
 
Comorbidities and Other Predictors for Severity of Colonic Diverticulitis?
Comorbidities and Other Predictors for Severity of Colonic Diverticulitis?Comorbidities and Other Predictors for Severity of Colonic Diverticulitis?
Comorbidities and Other Predictors for Severity of Colonic Diverticulitis?
 
PBM. MANEJO DE LA ANEMIA PREOPERATORIA. Dr García Erce. Roma 2015
PBM. MANEJO DE LA ANEMIA PREOPERATORIA. Dr García Erce. Roma 2015PBM. MANEJO DE LA ANEMIA PREOPERATORIA. Dr García Erce. Roma 2015
PBM. MANEJO DE LA ANEMIA PREOPERATORIA. Dr García Erce. Roma 2015
 
PBM. Preoperative Anemia Management, Dr García Erce. Roma 2015
PBM. Preoperative Anemia Management, Dr García Erce. Roma 2015PBM. Preoperative Anemia Management, Dr García Erce. Roma 2015
PBM. Preoperative Anemia Management, Dr García Erce. Roma 2015
 
Francesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor RiskFrancesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor Risk
 
Donor Selection: Sibling. Prof Miguel A Sanz
Donor Selection: Sibling. Prof Miguel A SanzDonor Selection: Sibling. Prof Miguel A Sanz
Donor Selection: Sibling. Prof Miguel A Sanz
 
Esrd in elderly patients 2019 latest
Esrd in elderly patients 2019 latestEsrd in elderly patients 2019 latest
Esrd in elderly patients 2019 latest
 
marcqi_blood_transfusion.pdfUNDERSTAND WORD FEATURE
marcqi_blood_transfusion.pdfUNDERSTAND WORD FEATUREmarcqi_blood_transfusion.pdfUNDERSTAND WORD FEATURE
marcqi_blood_transfusion.pdfUNDERSTAND WORD FEATURE
 
Hemodialysis.com | Kidney Disease | ESRD | Dialysis
Hemodialysis.com | Kidney Disease | ESRD | DialysisHemodialysis.com | Kidney Disease | ESRD | Dialysis
Hemodialysis.com | Kidney Disease | ESRD | Dialysis
 
Solid Organ Transplantation and HIV
Solid Organ Transplantation and HIVSolid Organ Transplantation and HIV
Solid Organ Transplantation and HIV
 

More from incucai_isodp

Jeremy Chapman - Australia - Tuesday 29 - Who Guiding Principles and quest fo...
Jeremy Chapman - Australia - Tuesday 29 - Who Guiding Principles and quest fo...Jeremy Chapman - Australia - Tuesday 29 - Who Guiding Principles and quest fo...
Jeremy Chapman - Australia - Tuesday 29 - Who Guiding Principles and quest fo...
incucai_isodp
 
Jeremy Chapman - Australia - Tuesday 29 - Hematopoietic Stem Cells
Jeremy Chapman - Australia - Tuesday 29 - Hematopoietic Stem CellsJeremy Chapman - Australia - Tuesday 29 - Hematopoietic Stem Cells
Jeremy Chapman - Australia - Tuesday 29 - Hematopoietic Stem Cells
incucai_isodp
 
Sharon Swain - USA - Wednesday 30 - Oral Presentations Misc. D
Sharon Swain - USA - Wednesday 30 - Oral Presentations Misc. DSharon Swain - USA - Wednesday 30 - Oral Presentations Misc. D
Sharon Swain - USA - Wednesday 30 - Oral Presentations Misc. Dincucai_isodp
 
Kathy Yandle - USA - Wednesday 30 - Oral Presentations Misc. D
Kathy Yandle - USA - Wednesday 30 - Oral Presentations Misc. DKathy Yandle - USA - Wednesday 30 - Oral Presentations Misc. D
Kathy Yandle - USA - Wednesday 30 - Oral Presentations Misc. Dincucai_isodp
 
Hedi Aguiar - USA - Wednesday 30 - Oral Presentations Misc. D
Hedi Aguiar - USA - Wednesday 30 - Oral Presentations Misc. DHedi Aguiar - USA - Wednesday 30 - Oral Presentations Misc. D
Hedi Aguiar - USA - Wednesday 30 - Oral Presentations Misc. Dincucai_isodp
 
Evelyn Alonzo - Venezuela - Wednesday 30 - Oral Presentations Misc. D
Evelyn Alonzo - Venezuela - Wednesday 30 - Oral Presentations Misc. DEvelyn Alonzo - Venezuela - Wednesday 30 - Oral Presentations Misc. D
Evelyn Alonzo - Venezuela - Wednesday 30 - Oral Presentations Misc. Dincucai_isodp
 
Chunhee Bok - Korea - Wednesday 30 - Oral Presentations Misc. D
Chunhee Bok - Korea - Wednesday 30 - Oral Presentations Misc. DChunhee Bok - Korea - Wednesday 30 - Oral Presentations Misc. D
Chunhee Bok - Korea - Wednesday 30 - Oral Presentations Misc. D
incucai_isodp
 
Bernadette Haase Kromwijk - The Netherlands - Wednesday 30 - Oral Presentatio...
Bernadette Haase Kromwijk - The Netherlands - Wednesday 30 - Oral Presentatio...Bernadette Haase Kromwijk - The Netherlands - Wednesday 30 - Oral Presentatio...
Bernadette Haase Kromwijk - The Netherlands - Wednesday 30 - Oral Presentatio...incucai_isodp
 
Jongwon Ha - Korea - Wednesday 30 - Oral Presentations Misc. C
Jongwon Ha - Korea - Wednesday 30 - Oral Presentations Misc. CJongwon Ha - Korea - Wednesday 30 - Oral Presentations Misc. C
Jongwon Ha - Korea - Wednesday 30 - Oral Presentations Misc. C
incucai_isodp
 
German Farfalli - Argentina - Wednesday 30 - Oral Presentations Misc. C
German Farfalli -  Argentina - Wednesday 30 - Oral Presentations Misc. CGerman Farfalli -  Argentina - Wednesday 30 - Oral Presentations Misc. C
German Farfalli - Argentina - Wednesday 30 - Oral Presentations Misc. Cincucai_isodp
 
Catarina Bolotinha - Portugal - Wednesday 30 - Oral Presentations Misc. C
Catarina Bolotinha - Portugal  - Wednesday 30 - Oral Presentations Misc. CCatarina Bolotinha - Portugal  - Wednesday 30 - Oral Presentations Misc. C
Catarina Bolotinha - Portugal - Wednesday 30 - Oral Presentations Misc. C
incucai_isodp
 
Annemarie Luchtenburg - The Netherlands - Wednesday 30 - Oral Presentations M...
Annemarie Luchtenburg - The Netherlands - Wednesday 30 - Oral Presentations M...Annemarie Luchtenburg - The Netherlands - Wednesday 30 - Oral Presentations M...
Annemarie Luchtenburg - The Netherlands - Wednesday 30 - Oral Presentations M...incucai_isodp
 
Alaleh Gheissari - Iran - Wednesday 30 -Oral Presentations Misc. C
Alaleh Gheissari - Iran - Wednesday 30 -Oral Presentations Misc. CAlaleh Gheissari - Iran - Wednesday 30 -Oral Presentations Misc. C
Alaleh Gheissari - Iran - Wednesday 30 -Oral Presentations Misc. Cincucai_isodp
 
Kirsten Howard - Australia - Wednesday 30 -Oral Presentations Misc. B
Kirsten Howard - Australia - Wednesday 30 -Oral Presentations Misc. BKirsten Howard - Australia - Wednesday 30 -Oral Presentations Misc. B
Kirsten Howard - Australia - Wednesday 30 -Oral Presentations Misc. Bincucai_isodp
 
Gwen O´Shaughnessy - USA - Wednesday 30 - Oral Presentations Misc. B
Gwen O´Shaughnessy - USA - Wednesday 30 - Oral Presentations Misc. BGwen O´Shaughnessy - USA - Wednesday 30 - Oral Presentations Misc. B
Gwen O´Shaughnessy - USA - Wednesday 30 - Oral Presentations Misc. B
incucai_isodp
 
Danielle Nijkamp - The Netherlands - Wednesday 30 - Oral Presentations Misc. B
Danielle Nijkamp - The Netherlands - Wednesday 30 - Oral Presentations Misc. BDanielle Nijkamp - The Netherlands - Wednesday 30 - Oral Presentations Misc. B
Danielle Nijkamp - The Netherlands - Wednesday 30 - Oral Presentations Misc. Bincucai_isodp
 
Azemi Barama - Canada - Wednesday 30 - Oral Presentations Misc. B
Azemi Barama - Canada - Wednesday 30 - Oral Presentations Misc. BAzemi Barama - Canada - Wednesday 30 - Oral Presentations Misc. B
Azemi Barama - Canada - Wednesday 30 - Oral Presentations Misc. Bincucai_isodp
 
Merve Tarhan - Turkey - Wednesday 30 - Oral Presentations Misc. A
Merve Tarhan - Turkey - Wednesday 30 - Oral Presentations Misc. AMerve Tarhan - Turkey - Wednesday 30 - Oral Presentations Misc. A
Merve Tarhan - Turkey - Wednesday 30 - Oral Presentations Misc. A
incucai_isodp
 
Sohal Ismail - The Netherlands - Wednesday 30 - Oral Presentations Misc. A
Sohal Ismail - The Netherlands - Wednesday 30 - Oral Presentations Misc. ASohal Ismail - The Netherlands - Wednesday 30 - Oral Presentations Misc. A
Sohal Ismail - The Netherlands - Wednesday 30 - Oral Presentations Misc. A
incucai_isodp
 
Liliana Bisigniano - Argentina - Wednesday 30 - Oral Presentations Misc. A
Liliana Bisigniano - Argentina - Wednesday 30 - Oral Presentations Misc. ALiliana Bisigniano - Argentina - Wednesday 30 - Oral Presentations Misc. A
Liliana Bisigniano - Argentina - Wednesday 30 - Oral Presentations Misc. A
incucai_isodp
 

More from incucai_isodp (20)

Jeremy Chapman - Australia - Tuesday 29 - Who Guiding Principles and quest fo...
Jeremy Chapman - Australia - Tuesday 29 - Who Guiding Principles and quest fo...Jeremy Chapman - Australia - Tuesday 29 - Who Guiding Principles and quest fo...
Jeremy Chapman - Australia - Tuesday 29 - Who Guiding Principles and quest fo...
 
Jeremy Chapman - Australia - Tuesday 29 - Hematopoietic Stem Cells
Jeremy Chapman - Australia - Tuesday 29 - Hematopoietic Stem CellsJeremy Chapman - Australia - Tuesday 29 - Hematopoietic Stem Cells
Jeremy Chapman - Australia - Tuesday 29 - Hematopoietic Stem Cells
 
Sharon Swain - USA - Wednesday 30 - Oral Presentations Misc. D
Sharon Swain - USA - Wednesday 30 - Oral Presentations Misc. DSharon Swain - USA - Wednesday 30 - Oral Presentations Misc. D
Sharon Swain - USA - Wednesday 30 - Oral Presentations Misc. D
 
Kathy Yandle - USA - Wednesday 30 - Oral Presentations Misc. D
Kathy Yandle - USA - Wednesday 30 - Oral Presentations Misc. DKathy Yandle - USA - Wednesday 30 - Oral Presentations Misc. D
Kathy Yandle - USA - Wednesday 30 - Oral Presentations Misc. D
 
Hedi Aguiar - USA - Wednesday 30 - Oral Presentations Misc. D
Hedi Aguiar - USA - Wednesday 30 - Oral Presentations Misc. DHedi Aguiar - USA - Wednesday 30 - Oral Presentations Misc. D
Hedi Aguiar - USA - Wednesday 30 - Oral Presentations Misc. D
 
Evelyn Alonzo - Venezuela - Wednesday 30 - Oral Presentations Misc. D
Evelyn Alonzo - Venezuela - Wednesday 30 - Oral Presentations Misc. DEvelyn Alonzo - Venezuela - Wednesday 30 - Oral Presentations Misc. D
Evelyn Alonzo - Venezuela - Wednesday 30 - Oral Presentations Misc. D
 
Chunhee Bok - Korea - Wednesday 30 - Oral Presentations Misc. D
Chunhee Bok - Korea - Wednesday 30 - Oral Presentations Misc. DChunhee Bok - Korea - Wednesday 30 - Oral Presentations Misc. D
Chunhee Bok - Korea - Wednesday 30 - Oral Presentations Misc. D
 
Bernadette Haase Kromwijk - The Netherlands - Wednesday 30 - Oral Presentatio...
Bernadette Haase Kromwijk - The Netherlands - Wednesday 30 - Oral Presentatio...Bernadette Haase Kromwijk - The Netherlands - Wednesday 30 - Oral Presentatio...
Bernadette Haase Kromwijk - The Netherlands - Wednesday 30 - Oral Presentatio...
 
Jongwon Ha - Korea - Wednesday 30 - Oral Presentations Misc. C
Jongwon Ha - Korea - Wednesday 30 - Oral Presentations Misc. CJongwon Ha - Korea - Wednesday 30 - Oral Presentations Misc. C
Jongwon Ha - Korea - Wednesday 30 - Oral Presentations Misc. C
 
German Farfalli - Argentina - Wednesday 30 - Oral Presentations Misc. C
German Farfalli -  Argentina - Wednesday 30 - Oral Presentations Misc. CGerman Farfalli -  Argentina - Wednesday 30 - Oral Presentations Misc. C
German Farfalli - Argentina - Wednesday 30 - Oral Presentations Misc. C
 
Catarina Bolotinha - Portugal - Wednesday 30 - Oral Presentations Misc. C
Catarina Bolotinha - Portugal  - Wednesday 30 - Oral Presentations Misc. CCatarina Bolotinha - Portugal  - Wednesday 30 - Oral Presentations Misc. C
Catarina Bolotinha - Portugal - Wednesday 30 - Oral Presentations Misc. C
 
Annemarie Luchtenburg - The Netherlands - Wednesday 30 - Oral Presentations M...
Annemarie Luchtenburg - The Netherlands - Wednesday 30 - Oral Presentations M...Annemarie Luchtenburg - The Netherlands - Wednesday 30 - Oral Presentations M...
Annemarie Luchtenburg - The Netherlands - Wednesday 30 - Oral Presentations M...
 
Alaleh Gheissari - Iran - Wednesday 30 -Oral Presentations Misc. C
Alaleh Gheissari - Iran - Wednesday 30 -Oral Presentations Misc. CAlaleh Gheissari - Iran - Wednesday 30 -Oral Presentations Misc. C
Alaleh Gheissari - Iran - Wednesday 30 -Oral Presentations Misc. C
 
Kirsten Howard - Australia - Wednesday 30 -Oral Presentations Misc. B
Kirsten Howard - Australia - Wednesday 30 -Oral Presentations Misc. BKirsten Howard - Australia - Wednesday 30 -Oral Presentations Misc. B
Kirsten Howard - Australia - Wednesday 30 -Oral Presentations Misc. B
 
Gwen O´Shaughnessy - USA - Wednesday 30 - Oral Presentations Misc. B
Gwen O´Shaughnessy - USA - Wednesday 30 - Oral Presentations Misc. BGwen O´Shaughnessy - USA - Wednesday 30 - Oral Presentations Misc. B
Gwen O´Shaughnessy - USA - Wednesday 30 - Oral Presentations Misc. B
 
Danielle Nijkamp - The Netherlands - Wednesday 30 - Oral Presentations Misc. B
Danielle Nijkamp - The Netherlands - Wednesday 30 - Oral Presentations Misc. BDanielle Nijkamp - The Netherlands - Wednesday 30 - Oral Presentations Misc. B
Danielle Nijkamp - The Netherlands - Wednesday 30 - Oral Presentations Misc. B
 
Azemi Barama - Canada - Wednesday 30 - Oral Presentations Misc. B
Azemi Barama - Canada - Wednesday 30 - Oral Presentations Misc. BAzemi Barama - Canada - Wednesday 30 - Oral Presentations Misc. B
Azemi Barama - Canada - Wednesday 30 - Oral Presentations Misc. B
 
Merve Tarhan - Turkey - Wednesday 30 - Oral Presentations Misc. A
Merve Tarhan - Turkey - Wednesday 30 - Oral Presentations Misc. AMerve Tarhan - Turkey - Wednesday 30 - Oral Presentations Misc. A
Merve Tarhan - Turkey - Wednesday 30 - Oral Presentations Misc. A
 
Sohal Ismail - The Netherlands - Wednesday 30 - Oral Presentations Misc. A
Sohal Ismail - The Netherlands - Wednesday 30 - Oral Presentations Misc. ASohal Ismail - The Netherlands - Wednesday 30 - Oral Presentations Misc. A
Sohal Ismail - The Netherlands - Wednesday 30 - Oral Presentations Misc. A
 
Liliana Bisigniano - Argentina - Wednesday 30 - Oral Presentations Misc. A
Liliana Bisigniano - Argentina - Wednesday 30 - Oral Presentations Misc. ALiliana Bisigniano - Argentina - Wednesday 30 - Oral Presentations Misc. A
Liliana Bisigniano - Argentina - Wednesday 30 - Oral Presentations Misc. A
 

Recently uploaded

What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?
Healthmedsrx.com
 
PGx Analysis in VarSeq: A User’s Perspective
PGx Analysis in VarSeq: A User’s PerspectivePGx Analysis in VarSeq: A User’s Perspective
PGx Analysis in VarSeq: A User’s Perspective
Golden Helix
 
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticalsacne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
MuskanShingari
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
Gokuldas Hospital
 
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory projectNano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
SIVAVINAYAKPK
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
Université de Montréal
 
Skin Diseases That Happen During Summer.
 Skin Diseases That Happen During Summer. Skin Diseases That Happen During Summer.
Skin Diseases That Happen During Summer.
Gokuldas Hospital
 
SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.
KULDEEP VYAS
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
ayushrajshrivastava7
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
Jim Jacob Roy
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Kunj Vihari
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
MuskanShingari
 
How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.
Gokuldas Hospital
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 

Recently uploaded (20)

What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?
 
PGx Analysis in VarSeq: A User’s Perspective
PGx Analysis in VarSeq: A User’s PerspectivePGx Analysis in VarSeq: A User’s Perspective
PGx Analysis in VarSeq: A User’s Perspective
 
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticalsacne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
 
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory projectNano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
 
Skin Diseases That Happen During Summer.
 Skin Diseases That Happen During Summer. Skin Diseases That Happen During Summer.
Skin Diseases That Happen During Summer.
 
SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
 
How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 

Alejandra Villamil - Argentina - Tuesday 29 - Organ Allocation Optimizing donor-recipient match

  • 1. 2011 Organ Donation Congress Buenos Aires Alejandra Villamil Hospital Italiano de Buenos Aires “ Donor Risk Index in Liver Transplantation”
  • 2. Liver Transplantation “ A dance for two”
  • 3. Liver Transplantation Ideal Donor Ideal Recipient Ideal “couple” Optimal patient and graft survival
  • 4. Ideal Donor Ideal Recipient Ideal “couple” Do we always get what we want? Optimal patient and graft survival
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11. The increase in the number of livers parallels an increase in the average DRI, corresponding to a decrease in organ quality Graft Quality in Adult Liver Transplants The historical perspective Median Donor Risk Index in successive years SRTR 2005
  • 12.
  • 13.
  • 14. Impact of donor quality on transplant outcomes “ Best organs for the sickest patients” Unable to survive the additional challenge of a poor quality organ SRTR Median Donor Risk Index (DRI)by MELD at Transplant Liver utilization practices
  • 15. Is it fair to expose the healthiest candidates, who benefit the least from transplantation, to bear the additional burden of high risk grafts? Impact of donor quality on transplant outcomes “ Worst organs for the healthiest patients”
  • 16. What is the impact of ECD across MELD Scores? Analysis of the outcome of transplantation with EDC (DRI >1.7) stratified by MELD Score The higher risk of graft failure for low quality organs remained stable across MELD categories The impact of suboptimal graft quality is not magnified by increased recipient severity Maluf, D.G. Transplantation 2006
  • 17. Combined impact of graft quality and disease severity Schaubel D, ATC 2006 Survival benefit for MELD >18 with high DRI organs Survival benefit for MELD >15 -17 with medium DRI organs Survival benefit for MELD >12 -14 with low DRI organs MELD <12 negative survival benefit from transplantation Intention to Treat analysis: What is the risk of doing the transplant with this graft versus the risk of not doing the transplant for a given recipient. Elective Risk of Death in first year Transplantation of the sickest candidates with lower quality livers may be justifiable and appropriate
  • 18. Combined impact of graft quality and disease severity Schaubel D, ATC 2006 Survival benefit for MELD >18 with high DRI organs Survival benefit for MELD >15 -17 with medium DRI organs Survival benefit for MELD >12 -14 with low DRI organs MELD <12 negative survival benefit from transplantation Intention to Treat analysis: What is the risk of doing the transplant with this graft versus the risk of not doing the transplant for a given recipient. Elective Risk of Death in first year Low MELD candidates transplantation with poor quality organs might be deleterious !
  • 19. Economic impact of ECDs on Transplantation High MELD score is the strongest predictor of liver transplant costs. Washburn W.K , Am J Transplant 2006. Axelrod, D.A. Am J Transplant 2007 DRI has been reported to increase hospital costs independently of the recipient status Average hospital charges by donor quality Sickest candidates High MELD score Poor quality organ High DRI + Higher costs Can we pay the price?
  • 20. Lucas McCormack, HPB World Congress 2010 Other alternatives for “ livers that nobody wants” Analysis of the experience in Hospital Aleman de Buenos Aires Are the two groups comparable? ECD could be an alternative for patients “underserved” by MELD Score distribution (ie HCC over Milan criteria, refractory ascites, HIV + patients) LNW (n=26) Control (n=25) p value Time in our LT Program (days) 53 (1-696) 42 (1-788) 0.72 Position on the WL 71 (31-432) 18 (2-29) <0.001 MELD score 13 (6-21) 18 (6-34) 0.02 MELD corrected 13 (6-21) 22 (7-34) <0.001 Donor risk factors (≤2 vs. 3-4 factors) 11/ 15 19/6 0.03
  • 21. Should donor and recipient be matched in liver transplantation?
  • 22. Ethics of ECD Which principles should guide allocation of ECDs? Maximize utility Maximize survival benefit Higher post Tx survival Considering in-list mortality and post Tx survival ECDs for low MELD scores ECDs for high MELD scores ALERT ! Deterioration of transplant outcomes among candidates with MELD < 20 has been attributed to the use of high DRI organs Volk, ECDs for other patients
  • 23. Which principles should guide allocation of ECDs? Decision making Recipient disease severity (MELD score) Donor quality (Donor Risk Index) Logistics Estimated ischemia time Opprtunity for another offer Consider time! Each decission should be taken in a case by case basis
  • 24. Disciplina de Transplante de Fígado - FMUSP n = 204 Prof. Dr. Luiz Augusto Carneiro D’Albuquerque ECDs: What proportion of the donor pool? The proportion of ECDs is expected to keep growing The Brazil example
  • 25. Meses % sobrevida USA SSESP American Transplant Registry ( Estado de São Paulo) Significant increase in ECDs is expected to impact transplant results Are doctors and patients ready to pay the prize? Prof. Dr. Luiz Augusto Carneiro D’Albuquerque The Brazil example ECDs: What proportion of the donor pool?
  • 26.
  • 27. The introduction of ECDs is today a most important strategy to fight organ shortage